SHYNDEC(SH:600420) Ge Long Hui·2025-12-09 08:28Core Viewpoint - The company Guoyao Modern (600420.SH) announced that its wholly-owned subsidiary, Jiangsu Weichida Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the marketing application of the raw material drug Agomelatine [1] Group 1: Company Developments - Guoyao Modern's subsidiary has been granted a marketing approval for Agomelatine, a drug primarily used for treating adult depression [1] - Agomelatine works by activating melatonin receptors MT1 and MT2 and antagonizing 5-HT2C, which helps restore disrupted biological rhythms and exerts antidepressant effects [1] Group 2: Industry Context - The approval of Agomelatine aligns with the growing demand for effective treatments for depression, highlighting the importance of innovative therapies in the pharmaceutical industry [1]